30. A method of making the antigen binding protein according to any one of Claims 1, 5, 9, 14, 19-22, and 24 comprising the step of preparing said antigen binding protein from a host cell that secretes said antigen binding protein.

31. A pharmaceutical composition comprising at least one antigen binding protein according to any one of Claims 1, 5, 9, 14, 19-22, and 24 and a pharmaceutically acceptable excipient.

32. The pharmaceutical composition of Claims 1, 5, 9, 14, 19-22, and 24 further comprising radioisotope, radionuclide, a toxin, a therapeutic agent, or a chemotherapeutic agent.

33. Use of an isolated antigen binding protein according to any of Claims 1, 5, 9, 14, 19-22, and 24 in the manufacture of a medicament ~~A method~~ for treating or preventing cancer ~~comprising administering to a patient in thereof an effective amount of at least one isolated antigen binding protein according to any of Claims 1, 5, 9, 14, 19-22, and 24~~.

34. Use of an isolated antigen binding protein according to any of Claims 1, 5, 9, 14, 19-22, and 24 in the manufacture of a medicament ~~A method~~ for treating or preventing a condition associated with at least one of elevated EGF and EGFR levels in a patient, ~~comprising administering to a patient in thereof an effective amount of at least one isolated antigen binding protein according to any of Claims 1, 5, 9, 14, 19-22, and 24~~.

35. The ~~method~~ use of claim 33 wherein the cancer is colorectal cancer.

36. The ~~method~~ use of claim 34 wherein the condition is colorectal cancer.

37. Use of an antigen binding protein according to any one of Claims 1, 5, 9, 14, 19-22, and 24 in the manufacture of a medicament for use in ~~A method of~~ inhibiting binding of EGFR to EGF in a patient ~~comprising administering an effective amount of at least one antigen binding protein according to any one of Claims 1, 5, 9, 14, 19-22, and 24~~.